Management of lung cancer brain metastasis: An overview

Management of lung cancer brain metastasis: An overview

With the improvements in systemic treatment for lung cancer, distant metastasis to sanctuary sites such as brain has become an increasingly more important issue. The management of these patients consists of supportive care and disease-directed treatment. Combined modality treatment (surgical resecti...

Full description

Bibliographic Details
Main Authors:	Himanshu Srivastava, Preety Negi, Pamela Alice Kingsley, Jaineet Sachdeva
Format:	Article
Language:	English
Published:	Thieme Medical Publishers, Inc. 2017-07-01
Series:	Asian Journal of Oncology
Subjects:	bevacizumab brain neoplasms combined modality therapy epidermal growth factor receptor nonsmall cell lung carcinoma receptor protein tyrosine kinase
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.4103/ASJO.ASJO_79_16

Similar Items

Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test
by: Kumar Prabhash, et al.
Published: (2017-01-01)

Clinical Observation of EGFR-TKI as A First-line Therapy on Advanced Non-small Cell Lung Cancer
by: Jianjie LI, et al.
Published: (2012-05-01)

Association between thyroid cancer and epidermal growth factor receptor mutation in female with nonsmall cell lung cancer
by: Seo Yun Kim, et al.
Published: (2017-01-01)

Clinical Study of Erlotinib in the Treatment of Patients with Advanced Stage Non-small Cell Lung Cancer
by: Renhua GUO, et al.
Published: (2009-12-01)

Clinical Experience with First-generation Epidermal Growth Factor Receptor  Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients  with Brain Metastasis
by: Huixing DONG, et al.
Published: (2017-02-01)

The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis
by: Chutong Lin, et al.
Published: (2021-04-01)

Recent Advances in Association of Estrogen and Non-small Cell Lung Cancer
by: Xiaosheng DING, et al.
Published: (2017-06-01)

Histological transformation of adenocarcinoma to small cell carcinoma lung as a rare mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors: Report of a case with review of literature
by: Monalisa Hui, et al.
Published: (2018-01-01)

A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer with Uncommon EGFR Mutations
by: Wenxing DU, et al.
Published: (2019-09-01)

Advances in Antiangiogenic Treatment of Advanced Non-squamous Non-small Cell Lung Cancer in 2017 ASCO and WCLC
by: Lianfang NI, et al.
Published: (2018-05-01)

Detection and Evaluation of EGFR Mutation Status in Serum of Patients with Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs
by: Ling MA, et al.
Published: (2013-06-01)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
by: Ping-Chih Hsu, et al.
Published: (2020-10-01)

Effects of EGFT-TKIs on Sequential Pemetrexed  for Advanced Pulmonary Adenocarcinoma
by: Xiangying WANG, et al.
Published: (2012-05-01)

Mechanism of TRIM24 to Regulate Resistance of Gefitinib in NSCLC cells
by: Haiying LI, et al.
Published: (2016-01-01)

Detection and Clinical Significance of Abundance of EGFR Mutation
by: Yi SHAO, et al.
Published: (2017-08-01)

Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer
by: Jun Ni, et al.
Published: (2016-01-01)

Adverse Events of Afatinib as First-line Treatment for Five Cases of Advanced Lung Adenocarcinoma and Review of Literature
by: Hong TAO, et al.
Published: (2014-04-01)

The Relationship between EGFR Mutations and Response and Prognosis of Tyrosine Kinase Inhibitors in Advanced Non-small-cell Lung Cancer
by: Xuebing LI, et al.
Published: (2008-04-01)

Research Progress on Resistance Mechanisms of Epidermal Growth Factor Receptor  Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
by: Yuan LI, et al.
Published: (2012-02-01)

Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
by: Lianfang NI, et al.
Published: (2018-02-01)

Application of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as the First-line Therapy in Patients with Advanced Non-small Cell Lung Cancer
by: Chunsun LI, et al.
Published: (2010-01-01)

The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
by: C.L. Watkins, et al.
Published: (2010-09-01)

Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
by: Laksmi Wulandari, et al.
Published: (2018-07-01)

Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
by: Soomin Ahn, et al.
Published: (2016-07-01)

Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors
by: Wenqiu ZHANG, et al.
Published: (2017-10-01)

Research Progress of New Generation EGFR-TKIs after Third-generation
by: Yuanyuan LIU, et al.
Published: (2020-11-01)

Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy  in Advanced NSCLC Patients with EGFR Mutations
by: Minjiang CHEN, et al.
Published: (2019-02-01)

The clinical outcome of brain metastases in nonsmall cell lung cancer patients with epidermal growth factor receptor mutation- A retrospective single-institution analysis
by: Cho-Hao Lee, et al.
Published: (2018-01-01)

Primary Application of Radiofrequency Ablation after Locally Progression of EGFR-TKIs in Non-small Cell Lung Cancer
by: Baodong LIU, et al.
Published: (2016-12-01)

Analysis of Treatment Response and Chest CT Characteristics for Patients Treated by EGFR-TKI in Relapse Advanced Lung Adenocarcinoma
by: Shuchang CHEN, et al.
Published: (2008-04-01)

Efficacy of Chemotherapy after EGFR-TKIs Resistance in 191 Patients with Unknow EGFR Gene Mutation in Advanced Lung Adenocarcinoma
by: Ping HE, et al.
Published: (2013-10-01)

Efficacy of erlotinib as first-line maintenance therapy in patients with locally advanced or metastatic nonsmall cell lung cancer who have not experienced disease progression or unacceptable toxicity during chemotherapy
by: Senthil Rajappa, et al.
Published: (2017-01-01)

Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis
by: Chaoyu HONG, et al.
Published: (2016-12-01)

Advances in the Research of Autophagy in EGFR-TKI Treatment and Resistance  in Lung Cancer
by: Qicheng ZHANG, et al.
Published: (2016-09-01)

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
by: Vanita Noronha, et al.
Published: (2020-01-01)

Research Progress of Targeted Therapy for HER2 Gene  in Advanced Non-small Cell Lung Cancer
by: Lingping KONG, et al.
Published: (2020-12-01)

Advances in Long Non-coding RNAs on Resistant to EGFR-TKIs  in Non-small Cell Lung Cancer
by: Shubin LI, et al.
Published: (2018-02-01)

Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation
by: Patel N, et al.
Published: (2017-06-01)

Research Progress of EGFR-TKI Therapy for Patients with Central Nervous System  Metastases from Non-small Cell Lung Cancer
by: Yinghua JIN, et al.
Published: (2016-08-01)

Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations
by: Qunhui WANG, et al.
Published: (2016-08-01)

Cannot write session to /tmp/vufind_sessions/sess_jv7sodsrlfaj98krd780b8smgr